Share this article
Share this article
SOUTH PLAINFIELD, N.J., April 14, 2021 /PRNewswire/ PTC Therapeutics, Inc. (NASDAQ: PTCT) today introduced a new no-charge, patient-initiated testing program in the United States for individuals who have symptoms consistent with, or a diagnosis of, cerebral palsy (CP) with no evidence of brain injury.
CP is a group of disorders that affect a person s ability to move and maintain balance and posture. Many of the common symptoms of CP are similar to other neurotransmitter disorders, such as Aromatic L-amino Acid Decarboxylase (AADC) deficiency, resulting in potential misdiagnosis. The program, PTC Pinpoint Direct™-CP Spectrum, is an innovative, genetic testing program which includes expert genetic counseling at no charge for eligible patients.
PTC Therapeutics to Host PTC518 Huntington Disease Deep Dive Webinar
News provided by
Share this article
Share this article
SOUTH PLAINFIELD, N.J., April 7, 2021 /PRNewswire/ PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webinar in its deep dive series discussing the PTC518 Huntington disease (HD) program on Thursday, April 15 at 9 a.m. E.T.
The Huntington Disease Deep Dive will provide an overview of PTC s splicing platform and the identification of molecules that have selectivity and specificity. PTC will highlight its Huntington program and the potential advantages of an orally bioavailable compound. PTC will discuss in detail the splicing modifier, PTC518, that is in an ongoing Phase 1 clinical trial. In preclinical studies, PTC518 has demonstrated broad biodistribution that uniformly reaches all regions of the brain and periphery and has shown reduction in Huntingtin protein (HTT) levels with a 1:1 correlation between blood and brain. PTC will also present prelimin
Share this article
Share this article
SOUTH PLAINFIELD, N.J., April 7, 2021 /PRNewswire/ PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has been named a winner of the 2021 Don Clifton Strengths-Based Culture Award from Gallup. The award recognizes organizations with strong workplace cultures that get the best out of their employees by focusing and developing their strengths and placing them at the center of how they work every day. We are honored to accept this award and appreciate the recognition that at PTC we have built an engaging and innovative work environment that is collaborative and committed to develop our employees, said Stuart W. Peltz, Ph.D., Chief Executive Officer of PTC Therapeutics. While the past year has presented many challenges due to the COVID-19 pandemic, our team has proven that we can work smarter and go farther together. At PTC we say that science is our foundation, and our culture is our heart.
Published: Apr 07, 2021
SOUTH PLAINFIELD, N.J., April 7, 2021 /PRNewswire/ PTC Therapeutics, Inc.. (NASDAQ: PTCT) today announced that it has been named a winner of the 2021 Don Clifton Strengths-Based Culture Award from Gallup. The award recognizes organizations with strong workplace cultures that get the best out of their employees by focusing and developing their strengths and placing them at the center of how they work every day. We are honored to accept this award and appreciate the recognition that at PTC we have built an engaging and innovative work environment that is collaborative and committed to develop our employees, said Stuart W. Peltz, Ph.D., Chief Executive Officer of PTC Therapeutics. While the past year has presented many challenges due to the COVID-19 pandemic, our team has proven that we can work smarter and go farther together. At PTC we say that science is our foundation, and our culture is our heart.
PTC Therapeutics Announces Commercial Milestone Payment Following the Recent European Approval of Evrysdi™
News provided by
Share this article
Share this article
SOUTH PLAINFIELD, N.J., April 1, 2021 /PRNewswire/ PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that a $20 million milestone payment was triggered by the first commercial sale of Evrysdi™ (risdiplam) in the European Union under its License and Collaboration Agreement with Roche. Approval for Evrysdi from the European Medicines Agency was received on March 30 for the treatment of spinal muscular atrophy (SMA) in adults and children 2 months and older. We are happy to see the rapid adoption of Evrysdi in the EU which speaks to the need for new treatments for SMA patients, said Stuart W. Peltz, Ph.D., Chief Executive Officer of PTC Therapeutics. We are delighted that an effective at-home therapy will be available to SMA patients. We recognize that a large proportion of SMA patients in the EU are current